Targeting iron assimilation to develop new antibacterials
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Since the first application of antibiotics to treat bacterial infections, the development and spread of resistance has been a persistent threat. An ever evolving pipeline of next-generation therapeutics is required for modern medicine to remain one step ahead of pathogens. AREAS COVERED: This review describes recent efforts to develop drugs that interrupt the assimilation of iron by bacteria: a process that is vital to cellular homeostasis and is not currently targeted by antibiotics used in the clinic. This review also covers the mechanisms by which bacteria acquire iron for their environment, and details efforts to intervene in these processes, using small molecule inhibitors that target key steps in these pathways, with a special emphasis on recent advances published during the 2010 - 2012 period. EXPERT OPINION: For decades, the routes used by bacteria to assimilate iron from host and environmental settings have been the subject of intense study. While numerous investigations have identified inhibitors of these pathways, many have stopped short of translating the in vitro results to in vivo proof of concept experiments. The extension of preliminary findings in this manner will significantly increase the impact of the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Molecular View of Microbial Diversity and the Biosphere
Pace, N. R. (1997) · Science · doi:10.1126/science.276.5313.734 · Cited by 3,188
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512 · cited 1×
“tremendous effort to develop compounds that act on highly conserved molecular processes and targets [90], but the future of the anti-infectives field may very well focus on therapeutics with limited coverage that interfere with disease- and strainspecific pathways and targets [90,91].”
BackgroundSiderophore-Based Iron Acquisition and Pathogen Control
Miethke, M., & Marahiel, M. A. (2007) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00012-07 · Cited by 1,774 · cited 1×
“Efforts to target pathways used by bacteria to acquire iron, where a remarkable amount of diversity is possessed, fall into this category [92].”
BackgroundHepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544 · cited 1×
“During times of iron sufficiency, excess atoms are stored in hepatocytes as insoluble salts within the subunits of ferritin and the overall homeostasis is regulated by hepcidin, a 25-residue peptide hormone [29].”
BackgroundIron Metabolism in Pathogenic Bacteria
Ratledge, C., & Dover, L. G. (2000) · Annual Review of Microbiology · doi:10.1146/annurev.micro.54.1.881 · Cited by 1,539 · cited 2×
“As the molecular details of iron retrieval pathways have been unveiled, it has been noted that genetic deletion mutants are unviable in an iron-limited setting, and in the case of human pathogens virulence is either ablated or markedly reduced [10,11].”
BackgroundGoetz, D. H., Holmes, M. A., Borregaard, N., Bluhm, M. E., Raymond, K. N., & Strong, R. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00708-6 · Cited by 1,355
Opening the Iron Box: Transcriptional Metalloregulation by the Fur Protein
Escolar, L., Pérez-Martín, J., & de Lorenzo, V. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.20.6223-6229.1999 · Cited by 815 · cited 1×
“The careful orchestration of these acquisition and storage pathways in bacteria are governed by the ferric uptake regulator (fur) that controls global changes in bacterial metabolism in response to iron limitation [12,13].”
BackgroundIron and Pseudomonas aeruginosa biofilm formation
Banin, E., Vasil, M. L., & Greenberg, E. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504266102 · Cited by 801
Regulation of iron transport and the role of transferrin
Gkouvatsos, K., Papanikolaou, G., & Pantopoulos, K. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.10.013 · Cited by 518
Lactoferrin a multiple bioactive protein: an overview
García-Montoya, I. A., Cendón, T. S., Arévalo-Gallegos, S., & Rascón-Cruz, Q. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.06.018 · Cited by 473
How pathogenic bacteria evade mammalian sabotage in the battle for iron
Fischbach, M. A., Lin, H., Liu, D. R., & Walsh, C. T. (2006) · Nature Chemical Biology · doi:10.1038/nchembio771 · Cited by 321 · cited 1×
“Numerous human proteins are known to bind to ferrisiderophores and limit their availability in the bloodstream [36].”
BackgroundThe pathogen-associated iroA gene cluster mediates bacterial evasion of lipocalin 2
Fischbach, M. A., Lin, H., Zhou, L., Yu, Y., Abergel, R. J., Liu, D. R., Raymond, K. N., Wanner, B. L., Strong, R. K., Walsh, C. T., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604636103 · Cited by 319 · cited 2×
“While the glucosyl appendages added by the Iro enzymes do not affect the triscatecholate’s high affinity for iron (vide supra), they reduce the Kd that NGAL diplays for the ferrisiderophore equivalent of 7 by >3 orders of magnitude [42].”
BackgroundResultSpellberg, B., Ibrahim, A. S., Chin-Hong, P. V., Kontoyiannis, D. P., Morris, M. I., Perfect, J. R., Fredricks, D., & Brass, E. P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr375 · Cited by 308
The iron chelator deferasirox protects mice from mucormycosis through iron starvation
Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32338 · Cited by 308 · cited 2×
“oryzae challenges of diabeticketoacidotic mice demonstrated that administration of 10 at 10 mg/kg twice daily displayed effectiveness in resolving the disease state similar to a treatment with liposomal amphotericin B [53].”
BackgroundStojiljkovic, I., Kumar, V., & Srinivasan, N. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01175.x · Cited by 230 · cited 1×
“While initial studies attributed the antibacterial activity of 25 to the release of the toxic transition-metal cargo [84,85], it was later discovered that 25 is incapable of being oxidized by heme monooxygenase [86] and may in fact exhibit its action through inhibition of this enzyme.”
BackgroundModun, B., & Williams, P. (1999) · Infection and Immunity · doi:10.1128/iai.67.3.1086-1092.1999 · Cited by 199
Crouch, M. V., Castor, M., Karlinsey, J. E., Kalhorn, T., & Fang, F. C. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.06089.x · Cited by 187 · cited 1×
“This further elaboration has no deleterious effects on the ability of the triscatecholate to bind iron, but provides an advantage to the bacterium with respect to the host’s innate immune defenses (vide infra) [21].”
BackgroundIn vitro characterization of IroB, a pathogen-associated C -glycosyltransferase
Fischbach, M. A., Lin, H., Liu, D. R., & Walsh, C. T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408463102 · Cited by 169 · cited 1×
“It has also been found that, prior to secretion, 3 can be further modified into a derivative siderophore, salmochelin S4 7 (Figure 3), by the addition of 1 or 2 C-linked glucosyl units [18-20].”
Neutrophil Gelatinase-associated Lipocalin, a Siderophore-binding Eukaryotic Protein
Borregaard, N., & Cowland, J. B. (2006) · BioMetals · doi:10.1007/s10534-005-3251-7 · Cited by 165
Review article: the iron overload syndromes
Siddique, A., & Kowdley, K. V. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05051.x · Cited by 162 · cited 1×
“Circulating iron is tightly bound by transferrin, where the holo-protein is efficiently captured by hepatocytes, stripped of its cargo, and the apo-protein shuttled back into the bloodstream [27,28].”
BackgroundZarember, K. A., Cruz, A. R., Huang, C.-Y., & Gallin, J. I. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01547-08 · Cited by 78 · cited 1×
“activity against Aspergillus fumigates, a fungal pathogen, and that it synergizes with clinically useful antifungals [51].”
BackgroundPRAMANIK, A., STROEHER, U., KREJCI, J., STANDISH, A., BOHN, E., PATON, J., AUTENRIETH, I., & BRAUN, V (2007) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.03.002 · Cited by 78
Cited by
Ito, A., Sato, T., Ota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 400
Bertrand, R. L. (2019) · Journal of Bacteriology · doi:10.1128/jb.00697-18 · Cited by 362
Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352
Thakur, N., Thakur, N., Kumar, A., Thakur, V. K., Kalia, S., Arya, V., Kumar, A., Kumar, S., & Kyzas, G. Z. (2024) · Science of The Total Environment · doi:10.1016/j.scitotenv.2023.169815 · Cited by 272
RetractedCell-surface signaling in Pseudomonas: stress responses, iron transport, and pathogenicity
Llamas, M. A., Imperi, F., Visca, P., & Lamont, I. L. (2014) · FEMS Microbiology Reviews · doi:10.1111/1574-6976.12078 · Cited by 176
Metadata
- Authors
- Foley, T. L., & Simeonov, A.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa Healthcare
- Published
- 2012-07-19
- Volume
- 7
- Issue
- 9
- Pages
- 831-847
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W1997083763
- Cited by
- 82
- References
- 22
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.